ReviewFrontiers in immunology2018

Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity.

Shingo Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.